Home › Funds › Bain Capital Life Sciences Investors, LLC › UPB
Bain Capital Life Sciences Investors, LLC position in UPB
UPSTREAM BIO INC · Health Care
Bain Capital Life Sciences Investors, LLC reported holding 600,949 shares of UPB (UPSTREAM BIO INC) in its Q2 2026 13F filing — a position valued at US$4.2M, representing 0.25% of its reported portfolio and ranking #20 among its reported holdings. Bain Capital Life Sciences Investors, LLC has disclosed UPB holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Bain Capital Life Sciences Investors, LLC's UPB position evolved
Bain Capital Life Sciences Investors, LLC first disclosed a stake in UPB in Q4 2024 at 2,295,322 shares (US$37.7M). The position peaked in Q3 2025 at 2,439,538 shares, worth US$45.9M. Across 7 filings, Bain Capital Life Sciences Investors, LLC increased the stake 1 time(s), trimmed it 3 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 600,949 shares valued at US$4.2M — a reduction of -266,262 shares quarter over quarter.. Notable position changes include a 46% trim in Q4 2025 (shares fell 67% over the following quarter), a 35% trim in Q1 2026 (shares fell 23% over the following quarter), a 31% trim in Q2 2026 (shares fell 24% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 2.30M | $37.74M | New |
| Q1 2025 | 2.30M | $14.05M | Hold |
| Q2 2025 | 2.44M | $26.79M | Add |
| Q3 2025 | 2.44M | $45.89M | Hold |
| Q4 2025 | 1.33M | $36.10M | Reduce |
| Q1 2026 | 867.21K | $7.80M | Reduce |
| Q2 2026 | 600.95K | $4.16M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About UPB and 13F data
UPB (UPSTREAM BIO INC) is a Health Care company. 56 other funds we track also report a position in UPB — the largest reported positions include ORBIMED ADVISORS LLC (US$39.4M), Decheng Capital LLC (US$18.9M), Enavate Sciences GP, LLC (US$17.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding UPB
- ORBIMED ADVISORS LLC 5.69M sh · $39.40M · Q2 2026
- Decheng Capital LLC 2.72M sh · $18.86M · Q2 2026
- Enavate Sciences GP, LLC 2.46M sh · $17.02M · Q2 2026
- Parkman Healthcare Partners LLC 935.25K sh · $6.47M · Q2 2026
- Samsara BioCapital, LLC 353.72K sh · $2.45M · Q2 2026
- Propel Bio Management, LLC 350.39K sh · $2.42M · Q2 2026
More on Bain Capital Life Sciences Investors, LLC
FAQ
How long has Bain Capital Life Sciences Investors, LLC held UPB?
Bain Capital Life Sciences Investors, LLC has disclosed UPB holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
What is Bain Capital Life Sciences Investors, LLC's current position in UPB?
As of Q2 2026, Bain Capital Life Sciences Investors, LLC holds 600.95K shares of UPB (UPSTREAM BIO INC), valued at $4.16M, representing 0.25% of its reported portfolio and ranking #20.
Has Bain Capital Life Sciences Investors, LLC been buying or selling UPB?
In the latest 13F filing (Q2 2026), Bain Capital Life Sciences Investors, LLC reduced its position in UPB. The position peaked in Q3 2025 at 2.44M shares.
Which other funds hold UPB?
Other major institutional holders of UPB include ORBIMED ADVISORS LLC, Decheng Capital LLC, Enavate Sciences GP, LLC, among 56 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.